GLP1R and atherosclerosis: Despite the growing body of literature, the evidence surrounding the CV efficacy of GLP-1 RAs, particularly semaglutide and exenatide, in patients with T2DM and established ASCVD remains scattered across multiple trials with varying outcome measures and study designs.